Publication:
Paper-based microchip electrophoresis for point-of-care hemoglobin testing

dc.contributor.authorMuhammad Noman Hasanen_US
dc.contributor.authorArwa Fraiwanen_US
dc.contributor.authorRan Anen_US
dc.contributor.authorYunus Alapanen_US
dc.contributor.authorRyan Ungen_US
dc.contributor.authorAsya Akkusen_US
dc.contributor.authorJulia Z. Xuen_US
dc.contributor.authorAmy J. Rezacen_US
dc.contributor.authorNicholas J. Kocmichen_US
dc.contributor.authorMelissa S. Crearyen_US
dc.contributor.authorTolulope Oginnien_US
dc.contributor.authorGrace Mfon Olanipekunen_US
dc.contributor.authorFatimah Hassan-Hangaen_US
dc.contributor.authorBinta W. Jibiren_US
dc.contributor.authorSafiya Gamboen_US
dc.contributor.authorAnil K. Vermaen_US
dc.contributor.authorPraveen K. Bhartien_US
dc.contributor.authorSuchada Riolueangen_US
dc.contributor.authorTakdanai Ngimhungen_US
dc.contributor.authorThidarat Suksangplengen_US
dc.contributor.authorPriyaleela Thotaen_US
dc.contributor.authorGreg Werneren_US
dc.contributor.authorRajasubramaniam Shanmugamen_US
dc.contributor.authorAparup Dasen_US
dc.contributor.authorVip Viprakasiten_US
dc.contributor.authorConnie M. Picconeen_US
dc.contributor.authorJane A. Littleen_US
dc.contributor.authorStephen K. Obaroen_US
dc.contributor.authorUmut A. Gurkanen_US
dc.contributor.otherDuke University Medical Centeren_US
dc.contributor.otherUniversity Hospitals Rainbow Babies & Children's Hospitalen_US
dc.contributor.otherMax Planck Institute for Intelligent Systemsen_US
dc.contributor.otherIndian Council of Medical Researchen_US
dc.contributor.otherUniversity Hospitals Case Medical Centeren_US
dc.contributor.otherUNC School of Medicineen_US
dc.contributor.otherUniversity of Michigan School of Public Healthen_US
dc.contributor.otherUniversity of Nebraska Medical Centeren_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherBayero Universityen_US
dc.contributor.otherCase Western Reserve Universityen_US
dc.contributor.otherThogus Productsen_US
dc.contributor.otherHEMEX HEALTH, INC.en_US
dc.contributor.otherHasiya Bayero Pediatric Hospitalen_US
dc.contributor.otherInternational Foundation Against Infectious Diseases in Nigeriaen_US
dc.contributor.othereHealth Africaen_US
dc.contributor.otherMurtala Muhammad Specialist Hospitalen_US
dc.date.accessioned2020-05-05T05:01:21Z
dc.date.available2020-05-05T05:01:21Z
dc.date.issued2020-04-07en_US
dc.description.abstract© The Royal Society of Chemistry 2020. Nearly 7% of the world's population live with a hemoglobin variant. Hemoglobins S, C, and E are the most common and significant hemoglobin variants worldwide. Sickle cell disease, caused by hemoglobin S, is highly prevalent in sub-Saharan Africa and in tribal populations of Central India. Hemoglobin C is common in West Africa, and hemoglobin E is common in Southeast Asia. Screening for significant hemoglobin disorders is not currently feasible in many low-income countries with the high disease burden. Lack of early diagnosis leads to preventable high morbidity and mortality in children born with hemoglobin variants in low-resource settings. Here, we describe HemeChip, the first miniaturized, paper-based, microchip electrophoresis platform for identifying the most common hemoglobin variants easily and affordably at the point-of-care in low-resource settings. HemeChip test works with a drop of blood. HemeChip system guides the user step-by-step through the test procedure with animated on-screen instructions. Hemoglobin identification and quantification is automatically performed, and hemoglobin types and percentages are displayed in an easily understandable, objective way. We show the feasibility and high accuracy of HemeChip via testing 768 subjects by clinical sites in the United States, Central India, sub-Saharan Africa, and Southeast Asia. Validation studies include hemoglobin E testing in Bangkok, Thailand, and hemoglobin S testing in Chhattisgarh, India, and in Kano, Nigeria, where the sickle cell disease burden is the highest in the world. Tests were performed by local users, including healthcare workers and clinical laboratory personnel. Study design, methods, and results are presented according to the Standards for Reporting Diagnostic Accuracy (STARD). HemeChip correctly identified all subjects with hemoglobin S, C, and E variants with 100% sensitivity, and displayed an overall diagnostic accuracy of 98.4% in comparison to reference standard methods. HemeChip is a versatile, mass-producible microchip electrophoresis platform that addresses a major unmet need of decentralized hemoglobin analysis in resource-limited settings.en_US
dc.identifier.citationAnalyst. Vol.145, No.7 (2020), 2525-2542en_US
dc.identifier.doi10.1039/c9an02250cen_US
dc.identifier.issn13645528en_US
dc.identifier.issn00032654en_US
dc.identifier.other2-s2.0-85082769702en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/54462
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85082769702&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemistryen_US
dc.subjectEnvironmental Scienceen_US
dc.titlePaper-based microchip electrophoresis for point-of-care hemoglobin testingen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85082769702&origin=inwarden_US

Files

Collections